Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix
- Determine the response, time to progression, disease free survival, and overall
survival of patients with recurrent and/or metastatic cancer of the cervix treated with
a combination of topotecan and paclitaxel.
- Determine the feasibility and toxicity of this regimen in these patients.
OUTLINE: Patients receive paclitaxel IV over 3 hours on day 1 and topotecan IV over 30
minutes on days 1-5. Filgrastim (G-CSF) is administered on days 6-14. Treatment repeats
every 21 days for a minimum of 2 courses in the absence of disease progression or
Patients are followed every 3 weeks.
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Amy D. Tiersten, MD
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
|Herbert Irving Comprehensive Cancer Center at Columbia University
|New York, New York 10032